User login
Targeting B-cell signaling pathways: a central role for Bruton’s tyrosine kinase
B-cell cancers constitute a large group of diseases with diverse clinical and pathological characteristics that arise from the B (bursal- or bone marrow-derived) lymphocytes of the immune system. B cells are involved in humoral immunity as part of the adaptive immune response. They display a unique B-cell receptor (BCR) on their surface which binds to a specific antigen. Antigen- binding activates the process of clonal expansion, during which the B cell reproduces to form an army of clones that secrete the same antibody. These antibodies then bind to the target antigen on foreign cells and initiate a range of immune responses that ultimately lead to the destruction of that cell.
Click on the PDF icon at the top of this introduction to read the full article.
B-cell cancers constitute a large group of diseases with diverse clinical and pathological characteristics that arise from the B (bursal- or bone marrow-derived) lymphocytes of the immune system. B cells are involved in humoral immunity as part of the adaptive immune response. They display a unique B-cell receptor (BCR) on their surface which binds to a specific antigen. Antigen- binding activates the process of clonal expansion, during which the B cell reproduces to form an army of clones that secrete the same antibody. These antibodies then bind to the target antigen on foreign cells and initiate a range of immune responses that ultimately lead to the destruction of that cell.
Click on the PDF icon at the top of this introduction to read the full article.
B-cell cancers constitute a large group of diseases with diverse clinical and pathological characteristics that arise from the B (bursal- or bone marrow-derived) lymphocytes of the immune system. B cells are involved in humoral immunity as part of the adaptive immune response. They display a unique B-cell receptor (BCR) on their surface which binds to a specific antigen. Antigen- binding activates the process of clonal expansion, during which the B cell reproduces to form an army of clones that secrete the same antibody. These antibodies then bind to the target antigen on foreign cells and initiate a range of immune responses that ultimately lead to the destruction of that cell.
Click on the PDF icon at the top of this introduction to read the full article.
Cost and response criteria are the new challenges
Although the concept of using immunotherapy to target an immune response against tumors is not new, this treatment modality is only now beginning to realize its full potential. Here, we take a look at the role of immunotherapy in cancer and some of the most exciting areas of clinical development.
*Click on the link to the left for a PDF of the full article.
Although the concept of using immunotherapy to target an immune response against tumors is not new, this treatment modality is only now beginning to realize its full potential. Here, we take a look at the role of immunotherapy in cancer and some of the most exciting areas of clinical development.
*Click on the link to the left for a PDF of the full article.
Although the concept of using immunotherapy to target an immune response against tumors is not new, this treatment modality is only now beginning to realize its full potential. Here, we take a look at the role of immunotherapy in cancer and some of the most exciting areas of clinical development.
*Click on the link to the left for a PDF of the full article.
Recent advances that are redefining oncology
Since President Richard Nixon declared war on cancer more than 40 years ago, there have been significant increases in the number of people who survive cancer. Alongside advances in screening, detection, and diagnosis, the development of targeted anticancer agents has been a major contributory factor to this success. We highlight some of the key developments that have shaped oncological practice in recent decades and those that will likely have a significant impact in the near future.
*Click on the link to the left for a PDF of the full article.
Since President Richard Nixon declared war on cancer more than 40 years ago, there have been significant increases in the number of people who survive cancer. Alongside advances in screening, detection, and diagnosis, the development of targeted anticancer agents has been a major contributory factor to this success. We highlight some of the key developments that have shaped oncological practice in recent decades and those that will likely have a significant impact in the near future.
*Click on the link to the left for a PDF of the full article.
Since President Richard Nixon declared war on cancer more than 40 years ago, there have been significant increases in the number of people who survive cancer. Alongside advances in screening, detection, and diagnosis, the development of targeted anticancer agents has been a major contributory factor to this success. We highlight some of the key developments that have shaped oncological practice in recent decades and those that will likely have a significant impact in the near future.
*Click on the link to the left for a PDF of the full article.